- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07949773
Peds Proton Therapy
Operational and Clinical Evaluation of the Treatment Planning Software and Oncology Information System for Pediatric Proton Therapy
This study is being done to evaluate the clinical utilization and safety of RayStation 2025 and RayCare 2025 treatment planning software upgrades when used to support standard-of-care proton therapy delivery in patients deemed clinically appropriate for such therapy by their treating radiation oncologist.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
In this study, the radiation treatment itself, including target definitions, prescription dose, treatment delivery, verification imaging, and adaptive treatment planning, is standard of care.
Current standard radiation therapy planning is based on a treatment plan generated from a planning computed tomography (CT) scan obtained before treatment begins. This plan is generally used for the entire course of therapy, with verification imaging performed during treatment primarily used to verify patient positioning rather than to recalculate delivered dose. On occasion, it is standard practice for a physician to determine, based on his or her interpretation of verification imaging, that an adaptive replanning of the treatment is needed to account for anatomic changes that the physician observes on verification imaging which mandate a change to the plan. Comprehensive software-based evaluation of the cumulative dose delivered over multiple fractions is not routinely performed in most clinical settings. Performing such evaluations typically requires manual steps including image registration, dose recalculation on additional imaging datasets, deformable dose mapping, and manual accumulation of dose across fractions. With currently FDA-approved tools for proton therapy treatment plan evaluation, these processes are time-consuming and require significant physics and physician resources. As a result, detailed adaptive dose evaluation is usually performed only in selected cases or as a one-time assessment during a treatment course, rather than as a routine component of daily clinical care.
The investigational component involves the prospective evaluation of the RayAdaptive and RayTracker software tools to assess their performance, reliability, usability, and clinical feasibility. These software features are not currently available for routine clinical use, being not yet FDA-cleared, in the configuration evaluated in this protocol and are being assessed in a defined prospective clinical research setting.
This is a nonrandomized, single arm, open-label, prospective interventional trial to determine the rate of adaptive replanning for proton therapy when RayTracker and RayAdaptive are used as decision-support tools in the analysis of every verification image obtained during each participant's proton therapy treatment course. This study will evaluate, under a defined prospective clinical research framework, the performance, reliability, usability, and clinical feasibility of implementing RayTracker and RayAdaptive - software components that have not yet been 510(k) cleared by the U.S. Food and Drug Administration (FDA).
Primary Objective
• To determine the frequency of adaptive replanning during proton therapy when RayTracker and RayAdaptive are incorporated into routine verification image review as clinical decision-support tools.
Secondary Objectives
- To evaluate the treating physician-reported rate at which RayTracker and RayAdaptive influenced the decision to pursue adaptive replanning during proton therapy.
- To explore concordance between RayAdaptive-predicted inadequate target coverage on verification imaging and findings on repeat CT simulation when performed.
- To explore concordance between RayAdaptive-predicted organ-at-risk dose constraint violations and findings on repeat CT simulation when performed.
- To report the incidence of adverse events (AEs) and device deficiencies related to the investigational RayTracker/RayAdaptive software.
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Research Team
- Telefonnummer: 608-915-1201
- E-post: clinicaltrials@cancer.wisc.edu
Studiesteder
-
-
Wisconsin
-
Madison, Wisconsin, Forente stater, 53792
- Rekruttering
- University of Wisconsin
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Age less than or equal to 17 years at the time of consent/assent.
- Patient has a clinical indication for radiation therapy, and the treating radiation oncologist has independently determined that proton therapy is clinically appropriate and has recommended proton therapy as part of the patient's routine clinical care, independent of participation in this research study. Proton therapy may be delivered with or without anesthesia when clinically indicated.
- Written informed consent will be obtained from adult subjects or the parent/legal guardian of pediatric subjects. Assent will be obtained from pediatric participants when appropriate according to institutional policy.
Exclusion Criteria:
- Patient has contraindications to proton therapy (per standard clinical guidelines).
- Patient is unable to comply with routine treatment workflow or follow-up.
- Patients who will be treated with a radiation plan of 5 fractions or fewer.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Standard of Care Proton Therapy
|
Part of a not yet FDA-cleared software, the RaySearch treatment planning system and RayCare oncology information system. RayTracker enables longitudinal evaluation of treatment by recalculating dose on daily images and accumulating dose across fractions using deformable image registration, thereby providing an estimate of the cumulative delivered dose to targets and organs at risk. RayAdaptive uses daily treatment imaging (such as cone-beam CT (CBCT)) together with the planning CT to generate an updated representation of patient anatomy and recalculation of dose on the current patient anatomy, allowing clinicians to evaluate whether anatomical changes could meaningfully alter the planned dose distribution. These features are designed to be used in tandem. Their combined capabilities are intended to support clinical decision-making related to treatment monitoring and potential adaptation. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Proportion of verification image assessments for each subject resulting in a clinical adaptive replanning decision
Tidsramme: up to 6 months
|
Defined as ordering repeat CT simulation and/or treatment plan reoptimization. |
up to 6 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Treating physician-reported influence of RayTracker/RayAdaptive on adaptive replanning decisions
Tidsramme: up to 6 months
|
Can I define this outcome to be: Did the RayTracker / RayAdaptive intervention influence your clinical decision? [Yes / No] This will be reported by physician count. |
up to 6 months
|
|
Concordance between RayAdaptive predictions of inadequate target coverage and findings on repeat CT simulation
Tidsramme: up to 6 months
|
up to 6 months
|
|
|
Concordance between RayAdaptive predictions of organ-at-risk dose constraint violations and findings on repeat CT simulation
Tidsramme: up to 6 months
|
up to 6 months
|
|
|
Incidence of AEs and device deficiencies
Tidsramme: up to 6 months
|
Incidence of AEs and device deficiencies at least possibly related to use of the investigational RayTracker/RayAdaptive software or its incorporation into the clinical workflow as assessed throughout the course of proton therapy and for 90 days following completion of proton treatment. Device deficiencies may include software malfunction, calculation error, deformable registration failure, software defect, or software limitations affecting treatment plan evaluation, image review, or data analysis. |
up to 6 months
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Brett Morris, MD, PhD, UW School of Medicine and Public Health
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- 2026-1312
- Protocol Version 7/26/26 (Annen identifikator: UW Madison)
- SMPH | Radiation Medicine (Annen identifikator: UW Madison)
- UW26111 (Annen identifikator: OnCore ID)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .